---
title: "Obefazimod (ABX464) in Ulcerative colitis: Co-prescribed/Concomitant therapies"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Co-prescribed/Concomitant therapies. Topics: Background oral 5-ASA and oral corticosteroids permitted at a stable dose in ABTECT induction, Concomitant therapies prohibited in ABTECT induction: immunosuppressants and advanced therapies, Concomitant oral corticosteroids in ABTECT maintenance: randomization stratification and baseline use, Corticosteroid-free clinical remission as a maintenance key secondary endpoint, and 1 further topic. 5 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/co-prescribed-concomitant-therapies"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Co-prescribed/Concomitant therapies

<a id="heading-2.1.2.12"></a>

## 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

### Background oral 5-ASA and oral corticosteroids permitted at a stable dose in ABTECT induction

> “At study entry, subjects randomized to any treatment group may continue certain background therapy for UC (e.g., 5-aminosalicylic acid [5-ASA] compounds and/or oral CS); therefore, even subjects randomized to the placebo treatment during the treatment period will have concomitant therapies that may be partially effective at controlling UC symptoms.”
> “For the treatment of UC (provided stable dose for at least 2 weeks prior to the screening endoscopy and during the whole induction study) the following medications are allowed upon entry into the study:”
> “Oral 5-ASA.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-2.1.2.12-2"></a>

### Concomitant therapies prohibited in ABTECT induction: immunosuppressants and advanced therapies

> “Cyclosporine, tacrolimus, mycophenolate mofetil, or thalidomide must be stopped at least 4 weeks prior to Screening endoscopy.”
> “Azathioprine or 6-mercaptopurine or methotrexate must be stopped at least 2 weeks prior to Screening endoscopy.”
> “Infliximab, adalimumab, golimumab, anti-TNF biosimilars, ozanimod, mirikizumab must be stopped at least 8 weeks prior to Screening endoscopy.”
> “Vedolizumab and ustekinumab or their biosimilars must be stopped at least 12 weeks prior to Screening endoscopy.”
> “Tofacitinib, filgotinib, upadacitinib, etrasimod must be stopped at least 2 weeks prior to Screening endoscopy.”
> “Antidiarrheals and motility agents (e.g., loperamide, diphenoxylate with atropine) must be stopped at least 2 weeks prior to Screening endoscopy.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-2.1.2.12-3"></a>

### Concomitant oral corticosteroids in ABTECT maintenance: randomization stratification and baseline use

> “Randomization stratification factors: clinical remission at maintenance baseline (yes/no), induction treatment (25 mg/50 mg), and maintenance baseline oral corticosteroids usage (yes/no)”

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

| Characteristic | Placebo | Obefazimod 25 mg | Obefazimod 50 mg |
| --- | --- | --- | --- |
| Corticosteroid use at maintenance baseline | “35.9%” | “41.5%” | “40.5%” |

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-2.1.2.12-4"></a>

### Corticosteroid-free clinical remission as a maintenance key secondary endpoint

> “Both doses of obefazimod met all key secondary endpoints (endoscopic improvement, endoscopic remission, HEMI1, corticosteroid free clinical remission, and sustained clinical remission), demonstrating robust and clinically meaningful efficacy results across multiple measures of disease control.”

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-2.1.2.12-5"></a>

### Combination therapy with obefazimod: preclinical evaluation

> “Throughout 2026, initial preclinical results from ongoing studies evaluating obefazimod in combination with other agents (currently targeted combination MOAs include IL-23, a4b7, PDE-4 and AhR) will be shared, with a lead combination candidate selected to advance into development by year-end.”

Source: [Abivax press release, 2026 corporate outlook (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-2026-corporate-outlook)

> “We have initiated a formal process evaluating oral and injectable combination therapy candidate with obefazimod in UC.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

> “End of 2026 IBD Combo Therapy Candidate Selection”

Source: [Abivax corporate presentation (2026)](https://ir.abivax.com/static-files/ecf996c4-f156-4dac-8e1e-5c4e7cfb8e7d)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
